NasdaqGS:BIIBBiotechs
Biogen (BIIB) Is Betting Its Next Phase Of Growth On Four New Drugs
Biogen (NasdaqGS:BIIB) is shifting its focus from older multiple sclerosis and Spinraza products to newer drugs in Alzheimer's, Friedreich’s ataxia, ALS, and depression.
The company is leaning on recently launched therapies such as Leqembi, Skyclarys, Qalsody, and Zurzuvae to help offset pressure on its legacy franchises.
This transition comes as competition from generics and biosimilars weighs on Biogen’s established revenue base.
Biogen sits at the center of several high-profile treatment...